Previous | Home | EndoTODAY | List | Next


[Splenic angiosarcoma]

Å©°Ô

Spleen, splenectomy: ANGIOSARCOMA, 10x10x5 cm
CD31: Positive in tumor cells
Factor VIII: Positive, focal in tumor cells


2013³â 6¿ù 28ÀÏ°ú 29ÀÏ°£ ÀϺ» ³ª°¡»çÅ°¿¡¼­ Á¦ 19ȸ ÀϺ»Ç︮ÄÚ¹ÚÅÍÇÐȸ Çмú´ëȸ(ÀϺ»¿¡¼­´Â ÇмúÁýȸ¶ó°í ºÎ¸¨´Ï´Ù)°¡ ¿­·È½À´Ï´Ù. ¿ì¸®³ª¶ó¿¡¼­´Â ÇÔ±â¹é±³¼ö´Ô°ú ¹Ú¼öÇå ±³¼ö´Ô²²¼­ ÃÊû¿¬ÀÚ·Î ÁÖÁ¦¹ßÇ¥¸¦ ÇÏ¼Ì°í ºÐ´ç¼­¿ï´ëº´¿ø fellow ¿Àµ¿Çö ¼±»ý´ÔÀÇ ±¸¿¬¹ßÇ¥°¡ ÀÖ¾ú½À´Ï´Ù. Á¦°¡ Èï¹Ì·Ó°Ô º¸¾Ò´ø Àӻ󿬱¸ ¸î °³¸¦ ¼Ò°³ÇÕ´Ï´Ù.

ÇÔ±â¹é ±³¼ö´Ô

¹Ú¼öÇå ±³¼ö´Ô

¹Ú¼öÇå ±³¼ö´Ô


ÁÖÀÎÀå ¼±Á¤ ÃÊ·Ï 1. µ¿°æµµ³» ´Ù±â°ü °øµ¿¿¬±¸

Áö³­ 10³â°£ 1Â÷ Á¦±ÕÄ¡·áÀÇ Á¦±ÕÀ²Àº º¯È­ÇÏÁö ¾Ê¾Ò°í 2Â÷ Á¦±ÕÄ¡·áÀÇ Á¦±ÕÀ²¸¸ °¨¼ÒÇÏ¿´´Ù´Â ³»¿ëÀÔ´Ï´Ù.

µ¿°æ Áö¿ª¿¡¼­ Áö³­ 10³â°£ 1Â÷ Á¦±ÕÄ¡·áÀÇ Á¦±ÕÀ²Àº °¨¼ÒÇÏÁö ¾Ê¾Ò½À´Ï´Ù. ±×·¯³ª per protocolÀÇ Á¦±ÕÀ²ÀÌ 80%¿¡ ¹ÌÄ¡Áö ¸øÇÏ°í intention to treatÀÇ Á¦±ÕÀ²Àº 70%¿¡ ¹ÌÄ¡Áö ¸øÇÏ¿´½À´Ï´Ù.

2Â÷ Á¦±ÕÄ¡·áÀÇ Á¦±ÕÀ²ÀÌ Á¡Â÷ °¨¼ÒÇÏ°í ÀÖ´Ù´Â Èï¹Ì·Î¿î µ¥ÀÌŸÀÔ´Ï´Ù. ƯÈ÷ °í·ÉÀÚ¿¡¼­ Á¦±Õ ¼º°ø·üÀÌ ³·¾Ò´Ù°í ÇÕ´Ï´Ù.


ÁÖÀÎÀå ¼±Á¤ ÃÊ·Ï 2. Hirosaki ´ëÇÐ Á¦±ÕÀ² ¿¬±¸

Áö³­ 10³â°£ 1Â÷ Á¦±ÕÄ¡·á¿Í 2Â÷ Á¦±ÕÄ¡·áÀÇ Á¦±ÕÀ²¿¡ º¯È­°¡ ¾ø¾ú´Ù´Â ³»¿ëÀÔ´Ï´Ù. µ¿°æÀÇ ´Ù±â°ü °øµ¿¿¬±¸¿Í ¹Ì¹¦ÇÑ Â÷ÀÌ°¡ ÀÖ¾î Èï¹Ì·Î¿ü½À´Ï´Ù.


ÁÖÀÎÀå ¼±Á¤ ÃÊ·Ï 3. MALT ¸²ÇÁÁ¾ È®´ë³»½Ã°æ ¼Ò°ß


ÁÖÀÎÀå ¼±Á¤ ÃÊ·Ï 4. Helicobacter Á¦±ÕÄ¡·á ÈÄ ¹ß»ýÇÑ pseudomembranous colitis


ÁÖÀÎÀå ¼±Á¤ ÃÊ·Ï 5 (S5-1). Influence on H. pylori eradication on evaluation of ABC health check system

Conclusion: Helicobacter pylori changed the evaluation of ABC health check system. It is necessary to establish a new evlaution of ABC after H. pylori eradication.

@ Related EndoTODAY: 2013³â 6¿ù 1ÀÏ ÇÑÀϳ»½Ã°æÇÐȸ Áß ABC screening °ü·Ã ºÎºÐ


ÁÖÀÎÀå ¼±Á¤ ÃÊ·Ï 5 (S5-2). A study on gastric cancer, H. pylori antibody negative and serum pepsinogen negative

Conclusion: In combination with Hp antibody and serum pepsinogen test, 91% cases of gastric cancer proved to be detected. Most casese of gastric cancer who were both methods negative seemed to have previous H. pylori infection in past years. To reduce false negative cases would be a problem.

49¸í Áß 47/¸í¿¡¼­ Kimura Takemoto classification C-2 ÀÌ»óÀÇ atrophy°¡ ÀÖ¾úÀ½.


ÁÖÀÎÀå ¼±Á¤ ÃÊ·Ï 6 (WS4-3). Hp eradication therapy without penicillin (µ¿°æ Hp ¿¬±¸È¸)

°á°ú: PMS (PPI + metronidazole + sitafloxacin) ¿ä¹ýÀÌ 29¿¹¿¡¼­ ½ÃÇàµÇ¾ú°í 28¸í(96.6%)¿¡¼­ ¼º°øÀûÀ¸·Î Á¦±ÕµÇ¾ú´Ù. PMC (PPI + metronidazole + clarithromycin) ¿ä¹ýÀº 50¿¹¿¡¼­ ½ÃÇàµÇ¾ú°í 29¸í(60.4%)¿¡¼­ ¼º°øÀûÀ¸·Î Á¦±ÕµÇ¾ú´Ù.

Conclusion: Triple therapy including PPI, metronidazole, and sitafloxacin is effectie and safe for Helicobacter pylori eradication in case of penicillin allergy.

@ Related EndoTODAY: 2013³â 6¿ù 1ÀÏ ÇÑÀϳ»½Ã°æÇÐȸ Áß sitafloxicin °ü·Ã ºÎºÐ

@ Related article: Hirata 2012, Matsuzaki 2012.


ÁÖÀÎÀå ¼±Á¤ ÃÊ·Ï 7 (P1-2). Characterization of novel Helicobacter pylori phages (KHP30, KHP40) from Japanese patients

Conclusion: So far, host range of novel spherical phage discovered in H. pylori isolates was ca 63%. Phage infection to non-H. pylori Helicobacter spp. and Campylobacter spp. was not observed. The phage is considered as a new type of spherical phage can not be classified in any existing virus category.


ÁÖÀÎÀå ¼±Á¤ ÃÊ·Ï 8 (S3-4). Efficacy of moxifloxacin-based & bismuth-containing therapy as second-line treatment for Hp. (ºÐ´ç¼­¿ï´ëº´¿ø ¿Àµ¿Çö)

Moxifloxacin + amoxicillin + PPI (7 days)56.4% (53/94)
Moxifloxacin + amoxicillin + PPI (14 days)75.4% (190/252)
Tetracyclin + metronidazole + bismuth + PPI (7 days)76.3% (286/375)
Tetracyclin + metronidazole + bismuth + PPI (14 days)81.9% (104/127)

Conclusion: Bismuth-containing quadruple therapy seems like more potent than moxifloxacin-based triple therapy in Korea.


ÁÖÀÎÀå ¼±Á¤ ÃÊ·Ï 9 (P3-2). Mutual interaction between protozoa and H pylori in co-culture

Conclusion: CO-culture of Hp with protozoa promoted aggregation and coccoid formation. Protozoa-Hp contacts were essential for this phenomenon. The mechanism for the result remains to be determined.


ÁÖÀÎÀå ¼±Á¤ ÃÊ·Ï 10 (P11-2). Clinical feature of reflux esophagitis after Hp eradication

Conclusion: The case of reflux esophagitis after Hp eradication was 13.4%. It was thought that high age, presenceof gastric ulcer and hiatal hernia, histological findings of high neurtophil infiltration and atrophy at antrum were the high risk of reflux esophagitis after Hp eradication.

@ Related PDF EndoTODAY: 2009³â 3¿ù 4ÀÏ Interesting combination


ÁÖÀÎÀå ¼±Á¤ ÃÊ·Ï 11 (S2-1). Prediction of ancient human migration by H. pylori

Conclusion: We performed phylogenetic analysis of Hp to predict the migration of host humans. We found Hp strains that have extremely old ancestry in Okinawa, which suggests early human migration to Ryukyu islands.

ÇÐȸ¿¡ ÇÔ²² Âü¼®ÇϽŠ¿©·¯ ±³¼ö´Ôµé


[2013-6-29. News1] [°Ç°­Ä®·³] Á¶±â À§¾Ï¿¡ ´ëÇÑ ³»½Ã°æ Ä¡·á -ÀÌÇõ ¿¬¼¼´ë ¼¼ºê¶õ½ºº´¿ø À§¾ÏŬ¸®´Ð ¼ÒÈ­±â³»°ú ±³¼ö- - ¸î ³â Àü¿¡ À§¾ÏÀ¸·Î °í»ýÇÏ´ø ÇÑ ¿©¹è¿ì°¡ ¿ì¸® °çÀ» ¶°³ª´Â ¾ÈŸ±î¿î ÀÏÀÌ ÀÖ¾ú´Ù. ¹Ý¸é ¾ó¸¶ Àü¿¡´Â ¿¹´ÉÇÁ·Î±×·¥¿¡¼­ À¯¸í°¡¼ö°¡ À§¾Ï Áø´ÜÀ» ¹Þ¾ÒÁö¸¸ ³»½Ã°æÀ¸·Î Ä¡·á¸¦ ÇÏ°í º°ÀϾøÀÌ ¿Õ¼ºÇÏ°Ô È°µ¿À» ÇÏ´Â °æ¿ì¸¦ º» ÀûÀÌ ÀÖ´Ù. °°Àº À§¾ÏÀÌ¶óµµ µÎ »ç¶÷ÀÇ °æ°ú´Â ¸Å¿ì ´Ù¸¥ ¾ç»óÀ» º¸ÀÎ °ÍÀ» ¾Ë ¼ö ÀÖ´Ù. À§¾ÏÀº ¿ì¸®³ª¶ó¸¦ Æ÷ÇÔÇؼ­ Àü¼¼°èÀûÀ¸·Î µÎ ¹ø°·Î ÈçÈ÷ ¹ß»ýÇÏ´Â ¾ÏÀ¸·Î ¿ì¸®³ª¶ó¿¡¼­ À§¾ÏÀ¸·Î ÀÎÇÑ »ç¸Á·üÀº ¼¼ ¹ø°·Î ³ô´Ù. ÀÌ·¯ÇÑ À§¾ÏÀº Á¶±â À§¾Ï°ú ÁøÇ༺ À§¾ÏÀ¸·Î ºÐ·ù°¡ °¡´ÉÇѵ¥ Ãʱ⿡ ¹ß°ßµÈ Á¶±â À§¾ÏÀº °æ°ú°¡ ÁÁ¾Æ¼­ ¿ÏÄ¡°¡ °¡´ÉÇÏ´Ù.

Àüü À§¾ÏȯÀÚ Áß¿¡¼­ ¿ÏÄ¡°¡ °¡´ÉÇÑ Á¶±â À§¾Ï ȯÀÚÀÇ ºñÀ²ÀÌ Å©°Ô Áõ°¡ÇÏ°í ÀÖ´Ù. ÀÌ´Â 40¼¼ À̻󿡼­ 2³â¸¶´Ù À§ °ËÁøÀ» ½ÃÇàÇÏ´Â ¿ì¸®³ª¶ó ±¹°¡¾Ï°ËÁø ÇÁ·Î±×·¥À¸·Î ÀÎÇÑ È¿°ú·Î ÆǴܵȴÙ. ÃÖ±Ù¿¡´Â Á¶±â À§¾ÏÀÇ ÀϺο¡¼­ ¼ö¼úÀ» ÇÏÁö ¾Ê°íµµ ³»½Ã°æ Ä¡·á¸¸À¸·Î ¿ÏÄ¡¸¦ ÇÒ ¼ö ÀÖ´Â ³»½Ã°æ Á¡¸·ÇÏ ¹Ú¸®¹ýÀ̶ó´Â »õ·Î¿î ±â¼úÀÌ ¸¹ÀÌ º¸±ÞÈ­µÅ Á¶±â ¹ß°ßÀ¸·Î ÀÎÇÑ ÀåÁ¡ÀÌ ´õ¿í Ä¿Áö°Ô µÆ´Ù.

»ç¶÷ÀÇ À§º®Àº Á¡¸·Ãþ, Á¡¸·ÇÏÃþ, ±ÙÀ°Ãþ, À帷ÇÏÃþ, À帷Ãþ µî ´Ù¼¸ ºÎºÐÀ¸·Î ±¸¼ºµÅ ÀÖ´Ù. À§¾ÏÀº À§Á¡¸·¿¡¼­ ¹ß»ýÇÏÁö¸¸ ½Ã°£ÀÌ Áö³ª¸é À§¾Ï¼¼Æ÷°¡ ÆÄ°íµé¾î Á¡¸·ÇÏÃþ, ±ÙÀ°Ãþ, À帷Ãþ µîÀ» Áö³ª À§ ¹ÛÀ¸·Î ÆÛÁö°í À§ ÁÖº¯ÀÇ ¸²ÇÁÀý·Îµµ ÆÛÁö°Ô µÈ´Ù. ÀÌ·¯ÇÑ À§¾Ï¼¼Æ÷°¡ ¾ÆÁ÷ Á¡¸·ÃþÀ̳ª Á¡¸·ÇÏÃþ¿¡¸¸ ±¹ÇѵŠÀÖ¾î ±ÙÀ°ÃþÀ¸·Î ħ¹üÀ» ÇÏÁö ¾ÊÀº °æ¿ì¸¦ Á¶±âÀ§¾ÏÀ̶ó°í ÇÑ´Ù. ÀÌ´Â À§¾ÏÀÌ ±ÙÀ°ÃþÀ̳ª À帷Ãþ±îÁö ÆÛÁø °æ¿ìº¸´Ù Ä¡·áµÉ ¼ö ÀÖ´Â °¡´É¼ºÀÌ ÈξÀ ³ô¾Æ¼­ ¼ö¼úÀ» ¹ÞÀ¸¸é 90~95% ÀÌ»ó ¿ÏÄ¡°¡ µÉ ¼ö ÀÖ´Ù.

°ú°Å Á¶±â À§¾ÏÀÇ Ä¡·á´Â ´ëºÎºÐ ¼ö¼úÀûÀ¸·Î À§¸¦ ÀýÁ¦ÇÏ´Â ¹æ¹ýÀÌ ÀÌ¿ëµÅ ¿Ô´Ù. ±×·¯³ª ¿äÁîÀ½ Á¶±â À§¾ÏÀÇ ÀϺΠȯÀÚµéÀº ³»½Ã°æ¸¸À¸·Î ¾Ï Á¶Á÷À» Á¦°ÅÇÏ´Â ½Ã¼úÀ» ¹Þ´Â °æ¿ì°¡ ¸¹¾ÆÁö°í ÀÖ´Ù. ƯÈ÷ ÃÖ±Ù¿¡ °³¹ßµÈ ³»½Ã°æ Á¡¸·ÇÏ ¹Ú¸®¹ýÀº Å©±â°¡ Å« Á¶±â À§¾ÏÀ» ³»½Ã°æÀûÀ¸·Î ÀýÁ¦ÇÏ´Â ¹æ¹ýÀÌ´Ù. Àü±âÀý°³µµ¸¦ ÀÌ¿ëÇØ º´º¯À» Á÷Á¢ ÀýÁ¦Çϱ⠶§¹®¿¡ Å©±â¿¡ Á¦ÇѾøÀÌ º´º¯À» ÀýÁ¦ÇÒ ¼ö ÀÖ´Â ÀåÁ¡ÀÌ ÀÖ¾î Á¶±â À§¾Ï ³»½Ã°æ Ä¡·áÀÇ Ç¥ÁØÀ¸·Î ÀÚ¸®Àâ°í ÀÖ´Ù. ³»½Ã°æÀ» ÀÌ¿ëÇØ Ä¡·áÇϹǷΠÀ§¾ÏÀýÁ¦ ÈÄ¿¡µµ À§¸¦ º¸Á¸ÇÒ ¼ö ÀÖ°í ¼ö¼ú°ú °ü·ÃµÈ ÈäÅͳª ÇÕº´ÁõÀÌ ¾ø´Ù. ½Ã¼ú½Ã°£ ¶ÇÇÑ Âª¾Æ¼­ ´ë°³ 30ºÐ¿¡¼­ 1½Ã°£ Á¤µµ ¼Ò¿äµÇ¸ç ÀϹÝÀûÀ¸·Î ½Ã¼ú ÈÄ 1ÁÖÀÏ À̳»¿¡ Åð¿øÀÌ °¡´ÉÇÏ´Ù.

¸ðµç À§¾ÏȯÀÚ¸¦ ³»½Ã°æ ÀýÁ¦¼ú·Î Ä¡·áÇÒ ¼ö ÀÖÀ¸¸é ÁÁ°ÚÁö¸¸ ³»½Ã°æÀ¸·Î´Â À§ÀÇ ¹Û¿¡ ÀÖ´Â ¸²ÇÁÀýÀ» ÀýÁ¦ÇÒ ¼ö ¾ø±â ¶§¹®¿¡ ¸ðµç À§¾ÏȯÀÚ¸¦ ³»½Ã°æÀûÀ¸·Î Ä¡·áÇÒ ¼ö ÀÖ´Â °ÍÀº ¾Æ´Ï´Ù. Áï À§¾Ï Áß¿¡¼­ ¸²ÇÁÀý ÀüÀÌÀÇ °¡´É¼ºÀÌ ¾ø´Â °æ¿ì¿¡ ÇÑÇØ ³»½Ã°æ ÀýÁ¦¼úÀ» ÇÒ ¼ö Àִµ¥ ´ÙÀ½ÀÇ Á¶°ÇÀ» ¸ðµÎ ¸¸Á·Çؾ߸¸ ¸²ÇÁÀý ÀüÀÌÀÇ °¡´É¼ºÀÌ °ÅÀÇ ¾ø¾î ³»½Ã°æ Á¡¸· ÀýÁ¦¼úÀÌ °¡´ÉÇÏ´Ù. ¸ÕÀú À§¾ÏÀÌ À§ÀÇÇ¥¸é(Á¡¸·Ãþ)¿¡ ±¹ÇѵŠÀÖ¾î¾ß ÇÑ´Ù. ¶Ç Á¶Á÷°Ë»ç¿¡¼­ ºÐÈ­°¡ ÁÁÀº ¾ÏÀ̾î¾ß Çϸç CT¿¡¼­ ¿ø°ÝÀüÀ̳ª ¸²ÇÁÀý ÀüÀÌ°¡ º¸ÀÌÁö ¾Ê¾Æ¾ß ÇÑ´Ù. µû¶ó¼­ ÁøÇ༺ À§¾ÏÀº ¿øÄ¢ÀûÀ¸·Î ³»½Ã°æ ÀýÁ¦¼úÀÌ ºÒ°¡´ÉÇÏ´Ù. ÃÖ±Ù ¿¬±¸¿¡ ÀÇÇÏ¸é ³»½Ã°æ ÀýÁ¦¼ú ´ë»óÀÌ µÇ´Â °æ¿ì´Â ¿Ü°úÀûÀÎ À§ ÀýÁ¦ ¼ö¼úÀ» ÇßÀ» ¶§ °á°ú¿Í ³»½Ã°æÀ¸·Î À§¾ÏÀ» ÀýÁ¦ÇßÀ» ¶§ °á°ú°¡ À¯»çÇÑ °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. Áï, Ä¡·á°á°ú°¡ ºñ½ÁÇϸ鼭µµ ¼ö¼ú¿¡ ºñÇØ ÀÔ¿ø±â°£ÀÌ Âª°í ¹«¾ùº¸´Ùµµ À§¸¦ º¸Á¸ÇÒ ¼ö ÀÖÀ¸¸ç À§ ÀýÁ¦¼ö¼ú ÈÄ¿¡ »ý±æ ¼ö ÀÖ´Â ÇÕº´ÁõÀÌ ¾ø´Ù´Â Á¡ µîÀ» °í·ÁÇÏ¸é ³»½Ã°æ ÀýÁ¦¼úÀº Á¶±â À§¾ÏȯÀÚ¿¡°Ô ¼ö¼úÀ» ´ë½ÅÇÒ ¼ö ÀÖ´Â ¸Å¿ì ÁÁÀº Ä¡·á¹ýÀ̶ó ÇÏ°Ú´Ù.

¹°·Ð ³»½Ã°æ ÀýÁ¦¼ú ÈÄ¿¡µµ ÀϺο¡¼­ ÇÕº´ÁõÀÌ ÀÖÀ» ¼ö Àִµ¥ ¾Ë·ÁÁø Áß¿äÇÑ ÇÕº´ÁõÀÎ ÃâÇ÷°ú õ°øÀÇ ¹ß»ý·üÀº 4% Á¤µµ·Î ¾Ë·ÁÁ® ÀÖ´Ù. ±×·¯³ª ´ëºÎºÐ ÃâÇ÷°ú õ°øÀº ³»½Ã°æÀ» ÀÌ¿ëÇØ Ä¡·á°¡ °¡´ÉÇÏ¸ç ¼ö¼úÀÌ ÇÊ¿äÇÑ °æ¿ì´Â ¸Å¿ì Àû´Ù.

Çѱ¹¿¡¼­ À§¾ÏÀÇ ¹ß»ýÀÌ ÁÙ°í´Â ÀÖÀ¸³ª ¾ÆÁ÷µµ ¹ß»ý·ü ¹× »ç¸Á·üÀÌ ³ô´Ù. ƯÈ÷ ¿ÏÄ¡°¡ °¡´ÉÇÑ Á¶±â À§¾ÏÀº Ưº°ÇÑ Áõ»óÀÌ ¾ø´Â °æ¿ì°¡ ¸¹±â ¶§¹®¿¡ ³»½Ã°æÀ» ÀÌ¿ëÇÑ °ËÁøÀÌ ¸Å¿ì Áß¿äÇÏ´Ù. Á¶±â¿¡ ¹ß°ßµÈ À§¾Ï¿¡ ´ëÇؼ­´Â ³»½Ã°æÀû Ä¡·á¸¦ ÅëÇØ ¿ÏÄ¡¿Í »îÀÇ Áú Çâ»óÀ̶ó´Â µÎ °¡Áö ¸ñÀûÀ» µ¿½Ã¿¡ ÀÌ·ê ¼ö ÀÖ´Ù. ¸ðµç À§¾ÏȯÀÚ¸¦ ³»½Ã°æÀ¸·Î Ä¡·áÇÒ ¼ö ÀÖ´Â °ÍÀº ¾Æ´ÏÁö¸¸ °¡´ÉÇÑ °æ¿ì¿¡´Â ¸¹Àº ÀåÁ¡À» °®°í ÀÖ´Ù.


[Âü°íÀÚ·á]

1) ´ëÇÑ»óºÎÀ§Àå°üÇ︮ÄÚ¹ÚÅÍÇÐȸ ÇмúÇà»ç Áö»óÁß°è

© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà